1.

纳入文献的基本特征

The characteristics of included studies

Study/Year	NCT no.	Design	Population	Size	Histology	PD-L1 cut-off	Target	ICIs	Control
NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; RCT: randomized controlled trial; PD-L1: programmed death ligand 1; PD-1: programmed death 1; CTLA-4: cytotoxic T-lymphocyte-asscociated antigen 4, CTLA-4.
Borghaei H. 2015[6]	NCT01673867	RCT/Phase 3	Stage IIIb/IV or recurrent non-squamous NSCLC	582	Non-squamous	1%, 5%, 10%	PD-1	Nivolumab	Docetaxel
Brahmer J. 015[7]	NCT02041533	RCT/Phase 3	Stage IIIb/IV squamous NSCLC	272	Squamous	1%, 5%, 10%	PD-1	Nivolumab	Docetaxel
Carbone D.P. 2017[8]	NCT02041533	RCT/Phase 3	Untreated stage IV or recurrent NSCLC, PD-L1≥1%	423	Any	1%, 5%	PD-1	Nivolumab	Chemotherapy
Wu Y.L. 2019[9]	NCT02613507	RCT/Phase 3	NSCLC that had progressed after platinum-based doublet chemotherapy	504	Any	1%	PD-1	Nivolumab	Docetaxel
Gandhi L. 2018[10]	NCT02578680	RCT/Phase 3	Metastatic non-squamous NSCLC without sensitizing EGFR or ALK mutations	616	Non-squamous	1%, 50%	PD-1	Pembrolizumab	Platinum-based chemotherapy
Herbst R.S. 2016[11]	NCT01905657	RCT/Phase 2/3	≥1% PD-L1 expression previously treated NSCLC	991	Any	1%, 50%	PD-1	Pembrolizumab	Docetaxel
Langer C. 2016[12]	NCT02039674	RCT/Phase 2	Untreated IIIb/IV non-squamous NSCLC without sensitizing EGFR or ALK mutations	123	Non-squamous	1%, 50%	PD-1	Pembrolizumab	Pemetrexed/ Carboplatin
Mok T.S.K. 2019[13]	NCT02220894	RCT/Phase 3	Previously treated locally advanced or metastatic NSCLC, PD-L1 TPS≥1%	1, 274	Any	1%, 20%, 50%	PD-1	Pembrolizumab	Platinum-based chemotherapy
Paz-Ares L. 2018[14]	NCT02775435	RCT/Phase 3	Untreated metastatic squamous NSCLC	559	Squamous	1%, 50%	PD-1	Pembrolizumab	Chemotherapy
Reck M. 2016[15]	NCT02142738	RCT/Phase 3	Untreated NSCLC, PD-L1≥50%, without sensitizing EGFR or ALK mutations	305	Any	50%	PD-1	Pembrolizumab	Platinum-based chemotherapy
Antonia S. 2017[16]	NCT02125461	RCT/Phase 3	Stage III NSCLC without disease progression after chemoradiotherapy	709	Any	-	PD-L1	Durvalumab	Chemotherapy
Fehrenbacher L. 2016[17]	NCT01903993	RCT/Phase 2	Progressed on post-platinum chemotherapy NSCLC	277	Any	1%, 5%, 50%	PD-L1	Atezolizumab	Docetaxel
Rittmeyer A. 2017[18]	NCT02008227	RCT/Phase 3	Previously treated IIIb/IV NSCLC	850	Any	1%, 5%, 50%	PD-L1	Atezolizumab	Docetaxel
Barlesi F. 2018[19]	NCT02395172	RCT/Phase 3	Stage IIIb or IV or recurrent NSCLC	792	Any	1%	PD-L1	Avelumab	Docetaxel
Lynch T. 2012[20]	Not Reported	RCT/Phase 2	chemotherapy-naïve IIIb/IV NSCLC	204	Any	-	CTLA-4	Ipilimumab	Chemotherapy
Govindan R. 2017[21]	NCT01285609	RCT/Phase 3	Stage IV or recurrent chemotherapy-naïve squamous NSCLC	749	Squamous	-	CTLA-4	Ipilimumab	Chemotherapy
Hellmann M. 2019[22]	NCT02477826	RCT/Phase 3	Stage IV or recurrent NSCLC previously untreated with chemotherapy	1739	Any	1%	PD-1/ CTLA-4	Nivolumab/ Ipilimumab	Chemotherapy